Kyverna Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KYTX research report →
About the company
Kyverna Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis.
- CEO
- Warner Biddle
- IPO
- 2024
- Employees
- 130
- HQ
- Emeryville, CA, US
Price Chart
- Market Cap
- $389.31M
- P/E
- -2.71
- P/S
- 0.00
- P/B
- 2.75
- EV/EBITDA
- -2.54
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -81.87%
- ROIC
- -71.42%
- Revenue
- $0 · 0.00%
- Net Income
- $-161,307,000 · -26.54%
- EPS
- $-3.64 · -9.31%
- Op Income
- $-169,827,000
- FCF YoY
- -32.00%
- 52W High
- $13.67
- 52W Low
- $2.52
- 50D MA
- $8.71
- 200D MA
- $8.07
- Beta
- 1.88
- Avg Volume
- 1.10M
Get TickerSpark's AI analysis on KYTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 27, 26 | CLARK IAN T | other | 5,093 |
| May 27, 26 | CLARK IAN T | other | 20,582 |
| May 27, 26 | Cohen Fred E | other | 5,093 |
| May 27, 26 | Cohen Fred E | other | 20,582 |
| May 27, 26 | SEIDENBERG BETH C | other | 5,093 |
| May 27, 26 | SEIDENBERG BETH C | other | 20,582 |
| May 27, 26 | Shaw Christi | other | 4,194 |
| May 27, 26 | Aktar Mert | other | 5,093 |
| May 27, 26 | Aktar Mert | other | 20,582 |
| May 18, 26 | Martini Gregory S. | other | 325,000 |
Our KYTX coverage
Recent articles, reports, and earnings notes.
No research on KYTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KYTX report →Similar companies
Peers in the same neighborhood.